A comparison of intra-articular hyaluronic acid competitors in the treatment of mild to moderate knee osteoarthritis.
Journal: Journal of Arthritis
Authors: McGrath AF, McGrath AM, Jessop ZM, Gandham S, Datta G, Dawson-Bowling S, Cannon SR.
“We conclude that intra-articular hyaluronic acid is a useful intervention in patients with mild to moderate osteoarthritis of the knee, can produce sustained pain relief at 6 months, and can reduce the requirement for analgesia and antiinflammatory medication during this time.”
A randomized saline-controlled trial of NASHA hyaluronic acid for knee osteoarthritis.
Journal: Current Medical Research and Opinion
Authors: Arden NK, Åkermark C, Andersson M, Todman MG, Altman RD.
“Single-injection NASHA was well tolerated and, although there was no significant benefit versus saline control in the primary analysis, post-hoc analysis showed a statistically significant improvement in pain relief at 6 weeks among patients without clinical effusion at baseline.”
Efficacy and safety of a single intra-articular injection of non-animal stabilized hyaluronic acid (NASHA) in patients with osteoarthritis of the knee.
Journal: Osteoarthritis and Cartilage
Authors: Altman RD, Åkermark C, Beaulieu AD, Schnitzer T, on behalf of the Durolane International Study Group.
“NASHA was not superior to placebo for the primary efficacy analysis. However, these data may be confounded by the inclusion of patients with osteoarthritis at other sites, as significant benefits over placebo were found among patients with osteoarthritis confined to the knee. Future trials of osteoarthritis that examine a local therapy might need to consider restricting the study population to those patients having osteoarthritis of only the signal joint.”
Elimination of stabilised hyaluronan from the knee joint in healthy men.
Journal: Clinical Pharmacokinetics
Authors: Lindqvist U, Tolmachev V, Kairemo K, Aström G, Jonsson E, Lundqvist H.
“The elimination kinetics of 131I-labelled NASHA from the human knee joint were described by three distinct phases, with half-times of 1.5 hours, 1.5 days and 4 weeks. Most likely, the last value reflects the true half-life of NASHA following intra-articular injection since the labelling method used causes minimal modification of hyaluronan.”
Full article available at PubMed.gov
Factors related with the time to surgery in waiting-list patients for knee prostheses.
Journal: Reumatología Cliníca
Authors: Romero Jurado M, Enrique Fidalgo A, Rodríguez Villar V, Mar Medina J, Soler López B.
“Factors like a lower age of the patient and the involvement of a single joint influenced the referral of the patient to surgery. The administration of viscosupplementation delayed the time until the patient was finally referred to surgery.”
NASHA hyaluronic acid vs methylprednisolone for knee osteoarthritis: a prospective, multi-centre, randomized, non-inferiority trial.
Journal: Osteoarthritis and Cartilage
Authors: Leighton R, Åkermark C, Therrien R, Richardson JB, Andersson M, Todman MG, Arden NK, on behalf of the DUROLANE Study Group.
“This study shows that single-injection NASHA was well tolerated and non-inferior to MPA [methylprednisolone acetate] at at 12 weeks. The benefit of NASHA was maintained to 26 weeks while that of MPA declined. An injection of NASHA at 26 weeks conferred long-term improvements without increased sensitivity or risk of complications.”
Non-animal stabilised hyaluronic acid in the treatment of osteoarthritis of the knee. A tolerability study.
Journal: Clinical Drug Investigation
Authors: Åkermark C, Berg P, Björkman A, Malm P.
“No safety concerns were raised in either the primary study or in the study extension. NASHA as an intra-articular therapyfor osteoarthritis of the knee appears to have an acceptable safety profile and thus merits further investigation regarding its long-term clinical efficacy.”
Reduction of arthrosis associated knee pain through a single intra-articular injection of synthetic hyaluronic acid.
Journal: Zeitschrift für Rheumatologie
Authors: Krocker D, Matziolis G, Tuischer J, Funk J, Tohtz S, Buttgereit F, Perka C.
“We conclude that a single-injection of Durolane can reduce arthrosis associated knee pain sufficiently. Our data are comparable with those published in clinical studies using other hyaluronic acids. The effects of Durolane are delayed but more sustained compared to those found for glucocorticoids. Because of the single-injection, we see an advantage in using Durolane compared to other conventional hyaluronic acids and glucocorticoids.”